Interactive Session:
80. Clinical Controversies in Infectious Diseases
Friday, October 21, 2011: 2:15 PM-4:15 PM
Room: Grand Ballroom (East-West)

Learning Objectives:

This interactive session will be broken down into three controversial topics.  For each topic addressed, the participants will be able to:

1.  First Line Therapy for HIV Disease

  • discuss new strategies for choosing ARV therapies in treatment naïve patients
  • understand viral replication and general principles of antiretroviral therapy when starting therapy
  • identify resistance and mutations to antivirals that may influence ARV therapy sequencing in HIV therapy and influence first line therapy

2.  Should we replace TSTs with IGRAs for TB screening?

  • differentiate the relative specificity and sensitivity of TSTs vs. IGRAs for TB screening in various populations
  • identify the relative cost-effectiveness of TSTs vs. IGRAs for TB screening 
  • explain the limitations of TSTs and IGRAs as screening tools for TB

3.  Do Probiotics have a role in the prevention of Nosocomial Infections?

  • identify the proposed mechanisms by which probiotics may decrease nosocomial infections
  • recognize the potential clinical applications for probiotics in hospitalized patients
  • explain the safety concerns associated with the use of probiotics

Target Audience: Pharmacists, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Hospital Epidemiologists, HIV Clinicians, Epidemiologists, Clinicians, Academicians

Tracks: Adult ID

Interactive Moderators:  Daniel McQuillen, MD, FIDSA, Lahey Clinic and Patrick Joseph, MD, FIDSA, ID Medical Group

CME Credits: Maximum of 2.0 hours of Category 1 credit possible

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-094-L01-P

Disclosures:

D. McQuillen, None

P. Joseph, None

C. Sears, None

D. Snydman, Wyeth Ayerst: Consultant, Consulting fee
Pfizer: Grant Investigator, Research support

L. M. Kawamura, None

J. A. Jereb, None

R. M. Gulick, Bristol-Myers: Consultant, Consulting fee
Gilead: Consultant, Consulting fee
GlaxoSmithKline: Consultant and Investigator, Consulting fee and Research grant
Merck: Consultant and Investigator, Consulting fee and Research grant
Pfizer: Consultant and Investigator, Consulting fee and Research grant
Tibotec: Consultant, Consulting fee
ViiV: Consultant, Consulting fee
Virostatics: Consultant, Consulting fee

J. Eron, Merck: Consultant and Grant Investigator, Consulting fee and Grant recipient
Bristol Myers Squibb: Consultant, Consulting fee
Tibotec/Jansen: Consultant, Consulting fee
ViiV/GSK: Consultant and Grant Investigator, Consulting fee and Research support
Tobira: Consultant and Grant Investigator, Consulting fee and Research support

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.